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Introduction: Berberine (BBR) is an isoquinoline plant alkaloid with demonstrated anti- 
inflammatory, anti-tumor and immunosuppressive pharmacological properties that functions via 
multiple signaling pathways and epigenetic modulators. Numerous studies have proposed BBR as 
a promising therapeutic agent for joint cartilage degeneration, and other connective tissue diseases.
Purpose and Methods: This work aimed to evaluate the effects of BBR on the growth and 
differentiation of embryonic skeletal progenitors using the limb mesoderm micromass culture 
assay.
Results: Our findings show that at difference of its apoptotic influence on a variety of tumor 
tissues, cell death was not induced in skeletal progenitors by the addition of 12 or 25 µM 
BBR concentration to the culture medium. Morphological and transcriptional analysis 
revealed dual and opposite effects of BBR treatments on chondrogenesis depending on the 
stage of differentiation of the cultured progenitors. At early stage of culture, BBR was 
a potent chondrogenic inhibitor, while chondrogenesis was intensified in treatments at 
advanced stages of culture. The chondrogenic promoting effect was accompanied by 
a moderate upregulation of gene markers of prehypertrophic cartilage, including ColXa1, 
alkaline phosphatase Alpl, Runx2, and Indian Hedgehog Ihh. We further observed a positive 
transcriptional influence of BBR in the expression of DNA methyltransferase genes, Dnmt1, 
Dnmt3a and Dnmt3b, suggesting a potential involvement of epigenetic factors in its effects.
Conclusion: Our study uncovers a new pharmacological influence of BBR in cartilage 
differentiation that must be taken into account in designing clinical protocols for its employ-
ment in the treatment of cartilage degenerative diseases.
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Introduction
The degenerative pathology of the locomotor system shows a high prevalence in 
occidental society due to the aging of the population, to the sedentary lifestyle, and 
to the practice of highly competitive sports. Joint cartilage, ligaments and tendons 
are major targets of such degenerative diseases. Regenerative medicine offers great 
expectations for the treatment of these diseases. However, the development of this 
therapy requires a detailed knowledge of the mechanisms that regulate the differ-
entiation and functional maintenance of skeletal tissues. Epigenetic regulators are 
emerging as major factors responsible for these functions.1
The embryonic limb provides a useful model for analyzing differentiation of 
skeletal tissues and for testing new therapeutic approaches. The early developing 
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limb is formed by a core of skeletal progenitors of 
somatopleural origin covered by ectoderm. During the 
development, progenitors are segregated into a core 
region that aggregate to form the cartilage templates of 
the skeleton and a peripheral population that remains 
undifferentiated under the influence of the ectodermal 
cover.2 The peripheral cell population forms the connec-
tive tissues associate with joints and muscles,3 or are 
eliminated by cell death.4 Most evidence indicate that 
the structural diversification of limb skeletal progenitors 
in vivo is regulated by epigenetic modifications via Wnt/ 
β-catenin signaling or by functional regulation of DNA 
methyl transferases.2,5,6 In vitro studies analyzing the 
chondrogenic differentiation of stem cells revealed impor-
tant and precocious transcriptional changes in the expres-
sion of pro-chondrogenic factors such as Sox9, Sox5, 
Sox6, and Runx2 via epigenetic modifications.7,8 In addi-
tion, SOX9 that is a master chondrogenic factor regulates 
itself the methylation status of downstream chondrogenic 
markers.9 Transcriptional changes regulated by epigenetic 
modifications are also associated with tendon differentia-
tion and aging,10,11 and with the progress of cartilage 
differentiation.12,13
Berberine (BBR) is a botanical alkaloid employed in 
traditional Chinese medicine that has been characterized as 
a promising therapeutic agent for numerous degenerative and 
inflammatory diseases, and also as anti-tumoral treatment for 
a variety of cancers.14–16 Among the pharmacological appli-
cations proposed for BBR are skeletal degenerative diseases, 
including joint cartilage degeneration and osteoarthritis,14–18 
intervertebral disc degeneration,19,20 and abnormal fibrosis.21
It is believed that the signaling pathways associated with 
inflammation are major molecular targets for the pharmaco-
logical effects of BBR.22 However, there is increasing evi-
dence showing that transcriptional gene regulations via 
epigenetic modifications sustain, at least in part, its pharma-
cological effects.23–26 It has been reported that BBR amelio-
rates cartilage degeneration via Wnt/β-catenin signal 
pathway,27 and exerts a potent antitumoral effect on multiple 
myeloma inducing the degradation of UHRF1 via the ubi-
quitin-dependent proteasome system.25 Considering that 
both β-catenin signaling and UHRF1 are important regula-
tors of differentiation of limb chondroprogenitors,2,28,29 and 
the proposed beneficial effect of BBR on cartilage 
degeneration,27 the aim of our study was to explore its effect 




The study was performed in high density cultures of skeletal 
progenitors (micromass cultures) obtained from the undiffer-
entiated mesoderm of the distal margin of the limb bud 
(“progress zone”) of chick (Rhode Island) embryos at 
4.5 day of incubation, equivalent to stages 24 and 25 HH. 
Fertilized eggs were obtained from a commercial farm 
(Granja Santa Isabel. Cordoba Spain) and embryo extraction 
was performed at the appropriate stage following the ethical 
recommendations of the European Communities Council. 
Embryos were washed in cold PBS and the most distal part 
of the hindlimb bud was dissected out. The tissue fragments 
were dissociated to single-cell level by treatment with 0.25% 
trypsin and 0.25% collagenase for 6 and 12 min respectively. 
The cellular suspension was then filtered through a 100 μm 
membrane and resuspended in Dulbecco’s Modified Eagle 
Medium (DMEM, Lonza) supplemented with 10% fetal 
bovine serum (FBS), 100 units/mL penicillin and 100mg/ 
mL streptomycin. 10 µL drops of cell suspension at 
a concentration of 2×104 cells/µL were pipetted into each 
well of a 48 well plate. Cells were allowed to attach for 2 
hours and then 200 µL of DMEM was added to each well. 
“Short term cultures” were incubated for 2 days in DMEM 
with or without 10% FBS. “Long-term cultures” were incu-
bated for 12 days in DMEM plus 10% FBS and 50mg/mL of 
ascorbic acid added to the medium from day 7 of culture. We 
have previously reported,30 that these culture periods corre-
sponds to pre-chondrogenic and pre-hypertrophic stages of 
cartilage differentiation.
At the end of the initial culture period, both short-term 
and long-term cultures were cultured for additional 6 hr in 
a medium containing 12.5 or 25 µM Berberine (BBR, 
Sigma-Aldrich) dissolved in DMSO. Control cultures 
were maintained for the same period in fresh medium 
lacking BBR but containing the same amount of DMSO. 
At the end of this period, cell proliferation and apoptosis 
were studied by flow cytometry and transcriptional 
changes were analyzed by Real-time quantitative PCR 
(qPCR). The phenotypic outcome of control and experi-
mental cultures was analyzed by cartilage specific staining 
with Alcian Blue or by histology after an additional 3 days 
of culture in drug-free medium.
Morphological Analysis
The chondrogenic differentiation of the cultures was ana-
lyzed by whole mount staining with 0.5% Alcian blue at 
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pH1.0 of cultures fixed in Kahle’s solution. The intensity 
of Alcian blue staining was quantified by colorimetric 
analysis at 600nm after dye extraction with 6 
M guanidine-HCl (pH 5.8). Each sample was a pool of 4 
micromasses. Data were analyzed by ANOVA followed by 
Bonferroni test for post-hoc comparisons and statistical 
significance was set at p<0.05.
For histology, micromasses were detached from the 
wells and embedded in araldite. 1µm thick sections were 
obtained and stained with Toluidine blue.
Cell senescence was evaluated detecting β- 
galactosidase activity at pH 6 (SAβ-gal) after overnight 
fixation in 4% glutaraldehyde following the recommenda-
tions of Debacq-Chainiaux et al.31 The SAβ-gal positive 
area in the central region of each culture was measured 
with Image J default tools and values were analyzed by 
ANOVA followed by Bonferroni test.
Apoptosis was evaluated by the terminal deoxynucleotidyl 
transferase-mediated dUTP-TRIC nick end labeling (TUNEL) 
assay using the in situ cell death detection kit (Roche).
Flow Cytometry
Control and BBR-treated cell cultures were dissociated 
with trypsin EDTA (Lonza). For propidium iodide (PI) 
staining, cells were washed with PBS, and fixed in 90% 
ethanol and stained overnight at 4°C with 0.1 mg/mL PI 
with 0.1% sodium citrate and 0.01% Triton X-100. The 
cell suspensions were subjected to flow cytometry in 
a Cytoflex (Beckman Coulter) with Cytexpert software 
for data collection and analysis. One million cells were 
used in each test. The gating strategy was made by dese-
lecting impurities (debris) using an SSC-A/IP-PE dot plot 
and then selecting the populations of apoptotic and living 
cells in a logarithmic scale IP-PE histogram (see 
Supplementary Figure 1). Data were analyzed by 
ANOVA followed by Bonferroni test for post-hoc compar-
isons. Statistical significance was set at p<0.05.
Real-Time Quantitative PCR (qPCR) for 
Gene Expression Analysis
For transcriptional analysis we selected a panel of genes 
including: master transcription factors of distinct connec-
tive tissues (Sox9, Scleraxis, Runx2, Tgif1, Ihh and Alpl); 
epigenetic regulators (Uhrf1, Uhrf2, Dnmt1, Dnmt3a, 
Dnmt3b and Tet3); cell senescence (p16, p21, p53, p63 
and p73); Tumor suppressor genes (Btg1 and Btg2); apop-
totic markers (Bak1); TGFβ ligands (Tgfβ2 and Tgfβ3); 
and a variety of extracellular matrix constituents and reg-
ulatory factors (Col1α1, Col2α1, ColXα1, Col27α1, 
Aggrecan, Decorin, the matricellular proteins Ccn1 and 
Ccn3, and the metalloprotease Mmp2).
Total RNA from Control or BBR-treated cultures was 
extracted using the NucleoSpin RNA Kit (Macherey- 
Nagel). RNA samples were quantified using 
a spectrophotometer ND-1000 (Nanodrop Technologies). 
First-strand cDNA was synthesized by RT-PCR using the 
RevertAid RT Kit (Thermo Scientific). The cDNA con-
centration measured in a spectrophotometer ND-1000 was 
adjusted to 0.5 µg/µL. SYBR Green qPCRs were per-
formed using the StepOne system (Life Technologies), 
with automation attachment, and the SYBR® Select 
Master Mix (Applied Biosystems). Gapdh had no signifi-
cant variation in expression across the sample set and 
therefore was chosen as the normalizer in our experiments. 
Mean values for fold changes were calculated for each 
gene. Each value in this work represents the mean ± SD 
of at least five independent samples obtained under the 
same conditions from at least 3 distinct experiments. 
Samples consisted of four micromass cultures. Student’s 
t-test was employed to analyze the statistical significance 
when control and experimental sample values differed 
more than 1.5 folds. Primers for qPCR are included in 
Supplementary Table S1.
Results
The micromass culture assay is a precursor of what we now 
term organoid cultures.32,33 Dissociated limb undifferen-
tiated skeletal progenitors cultured at high density in serum- 
free minimum essential medium or in medium containing 
10% fetal bovine serum recapitulates the events leading to 
the formation of the skeletal primordia except for the absence 
of the specific morphological shape of cartilages in vivo.34,35 
After two days of culture, cells aggregate forming small 
SOX9 and Alcian blue positive nodules. Cells in the peri-
nodular regions maintain a fibroblastic appearance. 
Consistent with this differentiation pattern, both Scleraxis 
and Sox9 genes are robustly expressed at these stages. 
Scleraxis is a marker of connective tissues that in vivo sur-
round the differentiating cartilaginous skeleton, including 
tendons, joint tissues, and aponeurosis.36 In subsequent 
days of culture, the chondrogenic nodules expand both in 
number and in size at expense of reducing the amount of 
peripheral fibroblastic tissue. The progression of chondro-
genesis is intense in cultures containing FBS and more lim-
ited when cultures are grown only in minimum essential 
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medium. After 10 days of culture in medium lacking FBS, 
and some days earlier in cultures containing FBS, cartilage 
specifically stainable by Alcian blue is the predominant 
tissue in the culture. In a previous study we observed that 
cultures of 2 and 12 days represent two distinct stages of 
cartilage differentiation. 2 days cultures contain prechondro-
genic cells in course of aggregation while 12 days cultures 
contain maturing cartilage in a prehypertrophic stage of 
differentiation.30 Consistent with these data, expression of 
Collagen type 2 alpha1 (Col2α1) and Aggrecan genes, that 
are master markers of chondrodifferentiation increased by 5 
and 7 folds respectively between day 2 and day 12 of culture 
(Fig. Supplementary 1). Considering these stages of cartilage 
differentiation, we performed treatments at early (short-term) 
and late stages (long-term) of culture to monitor the differ-
ences in the influence of BBR over the immature chondro-
progenitors versus differentiating chondrocytes. We 
analyzed the outcome and differentiation of the cultures 
and the transcriptional regulation that precede differences in 
chondrodifferentiation.
BBR Decreased Initial Stages of 
Chondrogenesis Favoring Fibroblastic 
Differentiation of Progenitors
Although the differentiation of the micromass cultures 
progressed much quicker in the presence of FBS than in 
its absence, in both cases, a 6hr treatment of BBR at the 
end of the second day of culture caused an intense inhibi-
tion of chondrogenesis detectable 3 days later. As shown 
in Figure 1, after three days of additional culture in BBR- 
free medium, the number, size, and staining intensity of 
the Alcian blue-positive nodules were reduced in BBR- 
treated micromasses (Figure 1A and C). Notably, the peri-
nodular fibroblastic tissue increased in a dose-dependent 
fashion in parallel with the reduction of the size of the 
Alcian blue positive nodules (Figure 1B, D, F–H). In 
tissue sections of control micromasses, cartilage nodules 
exhibit a well structural organization and are separated of 
each other by a reduced amount of internodular tissue 
(Figure 1B and F). In contrast, chondrogenic regions of 
BBR-treated cultures appeared less organized with zones 
having a rather fibrocartilaginous appearance with rounded 
chondrocytes rich in extracellular matrix intermingled with 
regions of dark cells lacking the morphological appearance 
of chondrocytes (Figure 1G–H). Quantification of the 
Alcian blue extracted by guanidine-HCl showed a 50% 
fall of chondrogenesis in cultures treated with 12.5 µM 
BBR (hereafter, “low-dose” of BBR) and 70% fall in 
25µM BBR treatments (hereafter “high-dose” of BBR) 
(Figure 1I).
Changes in cell proliferation, cell senescence and cell 
death together with transcriptional modifications preceding 
the different outcome of the treated cultures were analyzed 
at the end of the 6 hr period of BBR treatment in cultures 
growing in DMEM without FBS. Not statistically signifi-
cant changes in cell cycle, cell senescence or cell death 
between control and treated cultures were appreciated in 
this period, even in high-dose BBR treatments (Figure 1J, 
K, and Fig. Supplementary 2).
As shown in Table 1, we observed mild but significant 
transcriptional changes in genes associated with for cell 
differentiation, cell senescence, cell death, and epigenetic 
regulation. Independent of the doses selected, Tgfβ2 and 
Scleraxis were up regulated. Other genes belonging to the 
TGFβ pathway involved in fibrogenesis or the transcrip-
tion factor Runx2, which play a role at initial and at 
advanced stages of chondrogenic differentiation,35,37 
were not regulated. p21 and p53 genes, but not p16, that 
are developmental senescence central factors,38 were mod-
erately up-regulated although the pattern of SAβ-gal stain-
ing appeared only moderately intensified without reaching 
statistically significance (Fig. Supplementary 2). Tumor 
suppressor genes and the pro-apoptotic factor Bak1 were 
neither regulated at significant levels. Among the epige-
netic regulators, Dnmt1, 3a, and 3b were all significantly 
up regulated, but other epigenetic modulators were not. 
Extracellular matrix factors were not significantly 
regulated.
BBR Promotes Cartilage Maturation at 
Advanced Stages of Culture
Cartilage is the predominant component of micromasses 
cultured for 12 days. At this stage, the cultures were 
widely positive for Alcian blue staining showing nodules 
of intensified staining (Figure 2A). At difference of treat-
ments at earlier stages of culture (short-term), chondrogen-
esis appeared strongly intensified in cultures treated with 
low-dose BBR, (Figure 2B) and in a less intense fashion 
after treatment at high-dose of BBR (Figure 2C). In tissue 
sections, control and the low-dose treated experimental 
cultures showed similar appearance (Figure 2D–E). The 
high dose-dose treated cultures showed a slight prehyper-
trophic morphology (Figure 2F). Quantification of chon-
drogenesis after guanidine-HCl extraction of Alcian blue 
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Figure 1 Effects of BBR in 2-day cultures of limb skeletal progenitors. (A and B) Low magnification (A) and detailed view (B) of 5 days old micromass cultures after Alcian 
blue cartilage staining. (C and D) low magnification (C) and detailed (D) views of similar cultures to that shown in (A) but subjected to 12.5 µM BBR for a transitory 6hr 
period at the end of day 2. Note the intense decrease in Alcian blue positive cartilage nodules. (E) culture treated as in (D), but employing 25 µM BBR. Note the reduction in 
size and density of Alcian blue positive nodules at expenses of increasing regions occupied by cells negative for Alcian blue staining. (F–H) semithin sections of control (F) 
and experimental cultures treated with 12.5 µM BBR (G) and 25 µM BBR (H) to show the precise structural organization of the differentiating cartilage in the control 
culture (F) that contrast with a dose-dependent disorganized appearance of cultures subjected to 12.5 µM BBR (G) or 25 µM BBR (H). Note the diffuse transition of the 
cartilaginous tissue with the dark cells lacking the cellular an extracellular characteristics of differentiating cartilage in the treated micromasses (G and H). (I) quantitative 
analysis of Alcian blue dye in control and BBR treated cultures, after guanidine-HCl extraction (n=7). (J) graphic representation of the rate of cell death evaluated by flow 
cytometry in short term cultures treated for 6 hr with BBR versus untreated control cultures (represented by the dotted line). (K) graphic representation comparing the 
proportion of cells at the different stages of the cell cycle between treated and control cultures. Scale bars in (A and C) = 1mm; Scale bars in (B, D and E) = 400µm; scale 
bars in (F–H) = 40µm. Graphs in (I–K) represent the Mean ± SD. The dotted line represents values in control cultures. Differences were analyzed using ANOVA analysis. 
***p<0.001.
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confirmed and 50% of increased staining in cultures sub-
jected to low-dose of BBR (Figure 2G). The intensification 
of staining after high-dose BBR treatment was less intense 
reaching only a 25% (Figure 2G).
As observed in earlier stages of culture, no significant 
changes in cell death were appreciated after either low- or 
high-dose BBR treatments (Figure 2H). At difference of 
treatments at early stage of culture, a moderated slowing at 
phase S of the cell cycle, that not reached statistically 
significance, was appreciated after low-dose BBR treat-
ments (Figure 2I). We choose low-dose treatments for 
analyzing transcriptional changes (Table 2). Scleraxis, 
Tgfβ2, Tgfβ3 and Sox9 were all up regulated. Markers of 
cartilage hypertrophic maturation,39,40 including Collagen 
type X (ColXα1), Runx2, Ihh and alkaline phosphatase 
gene (Alpl), appeared also positively regulated. The epige-
netic marker Dnmt3b, but not other epigenetic regulators, 
appeared up regulated. Finally, senescence (p16, p21) 
apoptotic (Bak1) and the tumor suppressor Btg1 were 
also upregulated. Detection of SAβ-gal activity appeared 
moderately intensified after BBR treatments, but without 
reaching statistically significant differences (Fig. 
Supplementary 2).
Discussion
The embryonic limb mesodermal micromass culture assay 
is a powerful model for analyzing drugs of potential influ-
ence on the differentiation and maintenance of skeletal 
tissues. Limb skeletal progenitors are originated from the 
somatopleura and have potential to generate all the con-
nective tissues of the limb including, cartilage, tendons, 
ligaments, fasciae, joint capsules and intramuscular con-
nective tissue.3,41 Furthermore, in the absence of appro-
priate differentiation signals, skeletal progenitors are 
eliminated by senescence and massive cell death.4 
Importantly, the diversification of progenitors to form spe-
cialized cartilages, fibrous (dense) connective tissue, or 
being eliminated by cell death appears to be associated 
with epigenetic changes regulated by local signaling 
cascades.2,6,13,42
BBR has been characterized as a chondroprotective 
drug that ameliorates cartilage degeneration and joint 
rigidity in experimental models of osteoarthritis.43–45 
These findings together with other experimental 
approaches proposed that BBR could be effective for 
osteoarthritis treatment,17,22,27,46,47 intervertebral disc 
degeneration,20 and pathological fibrotic processes.9 
Abundant evidence indicates that the anti-inflammatory 
effect of BBR relays in the regulation of signaling path-
ways associated with inflammation.15,22 Cell death and 
cell cycle arrest of activated rheumatoid arthritis fibro-
blast-like synoviocytes in combination with an anti- 
apoptotic influence on chondrocytes were proposed to 
Table 1 Transcriptional Gene Regulation in Micromass Cultures 
Treated with BBR for 6 hr at Day 2 Compared with Control 
Untreated Micromass Cultures
2d+6h BBR
Gene 12.5 µM 25 µM
Differentiation
Sox9 1.35 ± 0.23 1.33 ± 0.21
Scleraxis 1.53 ± 0.39 * 1.93 ± 0.52 ***
Runx2 0.97 ± 0.32 0.70 ± 0.19
Tgif1 1.47 ± 0.29 1.24 ± 0.55
Apoptosis and Cell Cycle Regulation
p16 1.22 ± 0.39 1.34 ± 0.40
p21 1.80 ± 0.38 *** 5.04 ± 1.60 ***
p53 1.71 ± 0.62 ** 2.34 ± 0.81 *
p63 0.99 ± 0.30 0.95 ± 0.32
p73 0.92 ± 0.41 0.77 ± 0.33
Btg1 1.12 ± 0.26 1.21 ± 0.17
Btg2 1.07 ± 0.26 1.07 ± 0.28
Bak1 1.49 ± 0.51 1.47 ± 0.54
TGFβ signaling
Tgfβ2 1.52 ± 0.33 *** 1.79 ± 0.67 ***
Tgfβ3 1.18 ± 0.22 1.39 ± 0.21
Epigenetic modulators
Uhrf1 0.89 ± 0.22 0.94 ± 0.39
Uhrf2 1.29 ± 0.23 1.25 ± 0.33
Dnmt1 1.54 ± 0.27 *** 1.52 ± 0.22 ***
Dnmt3a 1.54 ± 0.29 *** 1.51 ± 0.19 ***
Dnmt3b 1.51 ± 0.32 ** 1.66 ± 0.43 ***
Tet3 1.15 ± 0.60 1.32± 0.68
ECM components
Ccn1 1.16 ± 0.17 1.32 ± 0.04
Ccn3 0.83 ± 0.19 0.60 ± 0.26
Col1α1 1.04 ± 0.27 1.06 ± 0.52
Col2α1 1.32 ± 0.30 1.41 ± 0.23
Col27α1 1.32 ± 0.32 1.32 ± 0.25
Mmp2 0.87 ± 0.23 0.82 ± 0.25
Decorin 1.19 ± 0.32 1.26 ± 0.13
Aggrecan 1.24 ± 0.44 1.23 ± 0.19
Notes: P-values marked with bold text indicate statistically significant differences 
between the groups: *p<0.05; **p<0.01; ***p<0.001.
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contribute also to the pharmacological effects of BBR on 
joint cartilage.44,48 Remarkably, the induction of cell cycle 
arrest and apoptosis constitutes the basis for the anti- 
tumoral pharmacological application of BBR in a variety 
of tumors.15 These pharmacological effects have been 
associated with transcriptional regulation of the pro- 
apoptotic and tumor suppressor genes, such as p53, p21, 
or Bax via inducing epigenetic modifications.15,24,48 These 
modifications included changes in DNA methylation,23 
inhibition of histone deacetylases binding,24 inhibition of 
the epigenetic regulatory factor Uhrf1,25 and transcrip-
tional up-regulation of demethylation (TET) enzymes.26
Three major findings concerning the pharmacological 
properties of BBR can be deduced from our results: 1) 
firstly, at difference of the apoptotic influence of BBR on 
a variety of tumoral tissues, no changes in cell death were 
detected in the micromass culture assay; 2) secondly, in 
concert with previous studies performed on a variety of 
normal or pathological tissues,43 we found that transcrip-
tional and phenotypic changes of treated cultures caused 
by BBR administration are associated with the stage of 
differentiation of cultured progenitors; and, 3), treatments 
with low doses of BBR performed in cultures at stages of 
cartilage maturation increased the chondrogenic process.
Figure 2 Effects of BBR in 12 days cultures of limb skeletal progenitors. (A–C) are low magnification views of 15 days old cultures stained with Alcian blue. (A) is a control 
culture. (B and C) are experimental cultures treated for 6 hr at day 12 with BBR at 12.5 µM (B) and 25µM (C). Note the increased cartilage staining in treated cultures. (D– 
F) semithin sections of control (D) and experimental cultures treated with 12.5 µM BBR (E) and 25µM BBR (F) showing a mild increased prehypertrophic appearance in 
cartilage subjected to high-dose treatment (F). (G) quantitative analysis of Alcian blue dye in control and BBR treated cultures, after guanidine-HCl extraction (n=5). (H) 
graphic representation of the rate of cell death evaluated by flow cytometry in long-term cultures treated for 6 hr with BBR versus untreated control cultures (represented 
by the dotted line). (I) graphic representation comparing the proportion of cells at the different stages of the cell cycle between treated and control cultures. Scale bar for 
(A–C)= 1mm; Scale bar for (D–F) = 30 µm. Graphs in (G–I) represent the Mean ± SD. The dotted line represents values in control cultures. Differences were analyzed 
using ANOVA analysis. **p<0.01; ***p<0.001.
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It has been found that the pro-apoptotic and anti- 
proliferative effects of BBR in breast cancer cells are not 
observed in non-malignant breast epithelial cells.49 The 
absence of increased cell death in our experimental assay is 
consistent with the reported chondroprotective influence of 
BBR,44 and supports the specificity of the dying influence of 
BBR on different cell lineages. As reported in different experi-
mental studies,22,48,50 we have observed a mild, but significant, 
transcriptional influence of BBR on genes associated with cell 
death and developmental cell senescence,51,52 including p21 
and Bak1, p53 and the tumor suppressor gene Btg1. This 
moderate gene up-regulation in our in vitro assay appeared 
insufficient to induce apoptosis or increased SAβ-gal activity 
in early or late cultures at the end of the 6 hr period of 
treatment.
The increased chondrogenesis observed after treat-
ments of cultures at advanced stages of cartilage differen-
tiation might be important when considering the 
therapeutic influence of BBR on joint cartilage 
degeneration.22 In our experimental model, BBR at initial 
stages of culture inhibited chondrogenesis, up-regulating 
pro-fibrogenic genes (Tgfβ2 and Scleraxis) but not Sox9, 
and maintained progenitors into a fibroblastic-like state. 
However, the addition of BBR to the culture medium at 
advanced stages of culture promoted chondrogenesis, 
deduced by the intensification of Alcian blue specific 
cartilage staining and by the transcriptional up-regulation 
of Sox9.
From a clinical point of view, a major question about 
the suitability of joint cartilage regenerative therapy con-
cerns the nature of the cartilaginous tissue resulting by the 
treatment.53 Our results do not presuppose that the influ-
ence of BBR in the micromass assay replicates its phar-
macological effects on adult pathologic cartilage but may 
be of help to uncover effects on degenerating cartilage of 
interest for therapeutics. The natural outcome of differen-
tiating cartilages in the course of skeletogenesis in vivo 
and in vitro is a sequential process evolving from pre- 
chondrogenic condensation to overt hypertrophy that is 
followed by osteogenic differentiation.53 We observed 
that ColXα1, Runx2, Ihh, and even Alpl genes, that are 
considered cartilage prehypertrophic markers, appeared up 
regulated in the late-stage treated cultures. However, the 
histological appearance of the cultures together with the 
twofold increased expression of Scleraxis, and the over-
expression of Ccn1 (Cyr61) genes, that are associated with 
the differentiation of progenitors in the contour of the 
developing cartilage,54 indicate that chondrogenic intensi-
fication was not fully dependent of a hypertrophic progres-
sion of cartilage differentiation. Consistent with this 
interpretation Sox9 gene, that is believed to counteract 
Table 2 Transcriptional Gene Regulation in Micromass Cultures 





Sox9 2.22 ± 0.47 *
Scleraxis 2.21 ± 0.96 *
Runx2 1.87 ± 0.56 ***
Tgif1 1.44 ± 0.51
Ihh 2.81 ± 1.35 **
Alpl 1.87 ± 0.48 ***
Apoptosis and Cell Cycle Regulation
p16 2.32 ± 0.97 *
p21 1.76 ± 0.66 **
p53 1.35 ± 0.82
p63 1.41 ± 0.93
p73 1.40 ± 0.65
Btg1 1.58 ± 0.45 **
Btg2 1.35 ± 0.70
Bak1 1.68 ± 0.25 **
TGFβ signaling
Tgfβ2 1.80 ± 0.76 *
Tgfβ3 1.98 ± 0.86 **
Epigenetic modulators
Uhrf1 1.14 ± 0.36
Uhrf2 1.29 ± 0.45
Dnmt1 1.14 ± 0.39
Dnmt3a 1.19 ± 0.52
Dnmt3b 2.06 ± 1.12 *
Tet3 1.21 ± 0.62
ECM components
Ccn1 1.51 ± 0.53 *
Ccn3 1.14 ± 0.52
Col1α1 1.29 ± 0.30
Col2α1 1.26 ± 0.59
ColXα1 1.57 ± 0.59 *
Col27α1 1.33 ± 0.45
Mmp2 1.33 ± 0.39
Decorin 1.02 ± 0.21
Aggrecan 1.07 ± 0.59
Notes: P-values marked with bold text indicate statistically significant differences 
between the groups: *p<0.05; **p<0.01; ***p<0.001.
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cartilage hypertrophy in the growth plate of long bones,55 
is maintained at high expression levels.
The regulation of Runx2 in later BBR treatments, merits 
especial attention. At the beginning of chondrogenic differ-
entiation Runx2 is required to sustain chondrogenesis, while 
once the cartilage is formed Runx2 promotes hypertrophy.40 
Therefore, the differential regulation of Runx2 in early and 
late cultures may reflect the stage-dependent opposite influ-
ence of BBR on chondrogenesis.
A further task of our study was to identify epigenetic 
factors as potential targets activated by BBR treatments. 
We identified Dnmt3b as an epigenetic target potentially 
implicated in the transcriptional influence of BBR in late 
cultures and also Dnmt1 and Dnmt3a in early cultures. 
However, at difference with studies on the anti-tumor 
influence of BBR,23 we detected a significant up- 
regulation, rather than down-regulation, of Dnmt3b. In 
addition, no transcriptional regulation of other epigenetic 
markers was appreciated in pro-chondrogenic treatments 
of BBR. Further studies are required to clarify this 
question.
Conclusion
Our study uncovers a pharmacological influence of BBR 
in the differentiation of the limb skeletal progenitors 
in vitro. The possibility that these effects were also 
induced in adult tissues during cartilage degenerative dis-
eases is a tempting hypothesis that may help to design 
protocols for the treatment of cartilages diseases.
Abbreviations
BBR, Berberine; DMEM, Dulbecco’s Modified Eagle 
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